Exponent, Inc. — Form 10-K Summary
Period clarification: The request identifies 2010 Q4, but the supplied filing is Exponent’s Form 10-K for the fiscal year ended December 30, 2011, with comparative fiscal 2010 results. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Business context and reporting period
Exponent provides multidisciplinary science and engineering consulting, including engineering and technology development, and environmental and health risk analysis. Its work includes litigation support, product safety and failure analysis, regulatory compliance, and research and design. Fiscal 2011, 2010 and 2009 each comprised 52 weeks.
Financial performance and liquidity
| Metric | FY 2011 | FY 2010 | Change |
|---|---|---|---|
| Revenue | $272.4 | $248.8 | +9.5% |
| Revenue before reimbursements | $246.7 | $221.9 | +11.2% |
| Operating income | $53.5 | $43.2 | +23.6% |
| Net income | $32.7 | $27.5 | +18.8% |
| Diluted earnings per share | $2.22 | $1.83 | +21.3% |
| Operating margin | 19.6% | 17.4% | +2.2 percentage points |
| Net margin | 12.0% | 11.1% | +0.9 percentage points |
| Operating cash flow | $46.6 | $36.1 | +$10.5 |
Revenue growth reflected higher billable hours and billing rates. Engineering and other scientific revenue rose 8.5% to $199.8 million; environmental and health revenue rose 12.5% to $72.7 million. Billable hours increased 9.0% to 981,000, and utilization rose to 71% from 70%. Management cited strong demand across practices and elevated activity on several large assignments.
Cash, cash equivalents and short-term investments totaled $109.7 million at year-end, compared with $106.5 million a year earlier. Working capital was $137.8 million; total assets were $268.8 million and stockholders’ equity was $186.7 million. The balance sheet reports no borrowings or debt; long-term liabilities were $21.3 million, including deferred compensation. Operating cash flow funded operations, while investing cash flow was negative $29.4 million, primarily reflecting purchases of short-term investments and $3.8 million of capital expenditures. Financing cash flow was negative $39.3 million, including $40.6 million of share repurchases. The company reported no cash dividends.
Segment operating income was $57.8 million for engineering and other scientific services and $22.4 million for environmental and health, before $26.7 million of corporate operating expense. EBITDA, a company-defined non-GAAP measure, was $59.0 million, or 23.9% of revenue before reimbursements, compared with $50.8 million, or 22.9%, in FY 2010.
Material changes versus FY 2010
- Operating and net income grew faster than revenue, with improved margins. Management attributed stronger profitability to utilization, cost management and leverage from major projects.
- Compensation expense increased 8.3% to $156.9 million, but declined as a share of revenue to 57.6% from 58.2%. Technical full-time-equivalent employees increased 6.6%.
- Other income, net, fell 60.8% to $1.4 million, principally because deferred-compensation plan investments recorded a $0.3 million loss versus a $1.9 million gain in FY 2010.
- Repurchases increased substantially to $40.6 million from $7.1 million; 1.002 million shares were repurchased during FY 2011. The board authorized an additional $35 million for repurchases in February 2012.
- Environmental and health grew faster than engineering and other scientific services; its utilization declined to 68% from 70% as the company added experienced staff.
Outlook, risks and unusual items
- No numerical revenue or earnings guidance is provided. Management expected average technical staffing and compensation expense to rise in FY 2012, with salary increases effective at the start of the second quarter. It also expected other operating and general and administrative costs to increase as it selectively hires and invests in infrastructure and business development.
- Management cautioned that some major assignments were expected to step down as they progressed through their project life cycles. Engagements can be postponed or terminated, and the small backlog is not a reliable forecast of future revenue.
- Principal risks include cyclical client demand and economic conditions, client payment and concentration risk, competition and pricing pressure, attracting and retaining technical staff, dependence on professional reputation, litigation and professional liability, potential conflicts that limit engagements, and regulatory changes or tort reform that could reduce demand. Government-contract audits, international operations, investment-market liquidity and potential asset impairment are additional risks.
- A former client may pursue claims relating to testimony by an Exponent employee in a prior case. The company said the potential loss could not be estimated, asserted it had strong defenses, and believed resolution would not materially affect its financial condition, results or liquidity. Exponent reported no material legal proceedings in Item 3.
- Year-end contractual commitments totaled $25.1 million, including $23.1 million of operating leases and $1.9 million of purchase obligations. Unrecognized tax benefits were $0.4 million; management said no resolution expected within 12 months was likely to materially affect results.
- The company reported no investment-portfolio impairment and no goodwill impairment. Its independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied document is FY 2011, not a 2010 Q4 filing.
- Review whether FY 2011’s strong growth and margin expansion are sustainable as large assignments wind down and hiring and compensation costs increase.
- Assess cash conversion, receivable collection and customer exposure; receivables were $73.1 million, including $25.1 million unbilled, and U.S. government agencies represented 12% of year-end receivables.
- Track the former-client potential claim and any changes to its currently unquantified exposure.
- Evaluate the pace and price of share repurchases, including the additional $35 million authorization, alongside staffing, investment and acquisition needs.